AKRO
Income statement / Annual
Last year (2024), Akero Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Akero Therapeutics, Inc.'s net income was -$252.06 M.
See Akero Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$29,000.00
|
$260,000.00
|
$244,000.00
|
$213,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$29,000.00
|
-$260,000.00
|
-$244,000.00
|
-$213,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$247.50 M
|
$141.80 M
|
$85.28 M
|
$81.76 M
|
$64.92 M
|
$37.05 M
|
$11.88 M
|
$3.49 M
|
| General & Administrative Expenses |
$37.93 M
|
$31.07 M
|
$29.87 M
|
$19.13 M
|
$15.24 M
|
$8.61 M
|
$1.90 M
|
$1.18 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$98,000.00
|
| Selling, General & Administrative Expenses |
$37.93 M
|
$31.07 M
|
$29.87 M
|
$19.13 M
|
$15.24 M
|
$8.61 M
|
$1.90 M
|
$1.08 M
|
| Other Expenses |
$0.00
|
$0.00
|
$3.86 M
|
$109,000.00
|
$947,000.00
|
$1.90 M
|
-$67.94 M
|
$0.00
|
| Operating Expenses |
$285.42 M
|
$172.87 M
|
$115.16 M
|
$100.89 M
|
$80.15 M
|
$45.65 M
|
$13.78 M
|
$4.56 M
|
| Cost And Expenses |
$0.00
|
$172.87 M
|
$115.16 M
|
$100.89 M
|
$80.15 M
|
$45.65 M
|
$13.78 M
|
$4.56 M
|
| Interest Income |
$0.00
|
$24.21 M
|
$3.86 M
|
$109,000.00
|
$947,000.00
|
$1.90 M
|
$0.00
|
$0.00
|
| Interest Expense |
-$4.67 M
|
$3.10 M
|
$739,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$29,000.00
|
$260,000.00
|
$244,000.00
|
$213,000.00
|
-$104,000.00
|
$13.78 M
|
$4.98 M
|
| EBITDA |
-$285.42 M |
-$148.63 M |
-$111.03 M |
-$100.53 M |
-$78.99 M |
-$45.65 M |
-$68.46 M |
-$232,363.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$33.36 M
|
$21.11 M
|
$3.12 M
|
$109,000.00
|
$947,000.00
|
$1.90 M
|
-$67.94 M
|
$0.00
|
| Income Before Tax |
-$252.06 M
|
-$151.76 M
|
-$112.03 M
|
-$100.78 M
|
-$79.21 M
|
-$43.76 M
|
-$81.71 M
|
-$4.56 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$3.12 M
|
-$41,000.00
|
-$17,000.00
|
$24,000.00
|
-$68.10 M
|
-$4.98 M
|
| Net Income |
-$252.06 M
|
-$151.76 M
|
-$108.91 M
|
-$100.74 M
|
-$79.19 M
|
-$43.76 M
|
-$81.71 M
|
-$4.56 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.75 |
-2.89 |
-2.79 |
-2.89 |
-2.52 |
-2.9 |
-3.85 |
-0.16 |
| EPS Diluted |
-3.75 |
-2.89 |
-2.79 |
-2.89 |
-2.52 |
-2.9 |
-3.85 |
-0.16 |
| Weighted Average Shares Out |
$67.14 M
|
$52.57 M
|
$38.98 M
|
$34.83 M
|
$31.46 M
|
$15.07 M
|
$21.22 M
|
$28.56 M
|
| Weighted Average Shares Out Diluted |
$67.14 M
|
$52.57 M
|
$38.98 M
|
$34.83 M
|
$31.46 M
|
$15.07 M
|
$21.22 M
|
$28.56 M
|
| Link |
|
|
|
|
|
|
|
|
